Agreement - May 2, 2017
Lundbeck in conditional agreement and divests part of its headquarters
H. Lundbeck has signed a conditional agreement regarding the sale of properties (approximately 33,000 m2) on the Valby site in Copenhagen to the Danish pension funds Juristernes og Økonomernes Pensionskasse (JØP) and Danske civil- og akademiingeniørers Pensionskasse (DIP). Provided that the pre-specified conditions are met, Lundbeck will receive a cash payment of DKK 378 million […]
Agreement - April 21, 2017
Scandinavian Biopharma in agreement with Flynn Pharma
Scandinavian Biopharma has entered into an agreement with Flynn Pharma for the viper antivenom ViperaTAb. Under the agreement, Scandinavian Biopharma will have exclusive rights to service and make ViperaTAb available for emergency use in the Nordics, Baltic States and Germany. “We are very pleased to strengthen our portfolio with an important antivenom for Northern Europe” […]
Agreement - March 14, 2017
Bonesupport extends US distribution agreement
BONESUPPORT has extended the term of its U.S. distribution agreement with Zimmer Biomet, where Zimmer will continue to have exclusive rights for BONESUPPORT’s cerament bone void filler product line for Orthopedics, Trauma and Foot and Ankle indications in the United States. “We are extremely pleased to extend our distribution agreement with Zimmer Biomet,” said Richard […]
Agreement - March 3, 2017
MedImmune forms development alliance with Sanofi Pasteur
Medimmune and Sanofi Pasteur have announced an agreement to develop and commercialise MEDI8897, a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV,) jointly. MEDI8897 is currently in a Phase IIb clinical trial in pre-term infants who are ineligible for Synagis, the current standard of care medicine, […]
Agreement - February 27, 2017
Vironova signs agreement with the FDA
Vironova signs one-year agreement with the U.S. Food and Drug Administration to beta test proprietary Vironova Analyzing Software (VAS). In one of the fastest growing drug development areas today, nano-particles (for example liposomes), visible using electron microscopy, are used to deliver drugs to their exact targets in the body. Vironova Analyzing Software (VAS) in combination […]
Agreement - February 24, 2017
NeuroVive appoints scientific advisors and enters research agreement
NeuroVive Pharmaceutical announces two new research agreements and the appointment of Professor Philippe Gallay, PhD, and Professor Massimo Pinzani, MD, PhD, FRCP, as scientific advisors. The aim of the agreements is to further explore NeuroVive’s new drug compounds in development for the treatment of NASH and hepatocellular carcinoma (HCC). In the new collaboration with Philippe […]
